Synthorx, Inc.
Officers & Directors
1. Laura Shawver: Chief Executive Officer and Director
2. Marcos Milla: Chief Scientific Officer
3. Robby E. Weimer IV: Chief Financial Officer
4. Rachel H. Allen: Senior Vice President, General Counsel and Corporate Secretary
5. Jeffrey D. Stein: Independent Director
6. Jami Rubin: Independent Director
Dirk Van Den Boom: Independent Director
Laura Shawver, the CEO of Synthorx, formerly worked as a CEO and President of Cleave Biosciences, a company focused on developing cancer therapies. Prior to joining Cleave Biosciences, Shawver was a co-founder of Phenomix Corporation, where she served as CEO and President until 2009. Shawver has also been a part of a non-profit organization named The Clearity Foundation.
Marcos Milla has joined Synthorx Inc as Chief Scientific Officer in He has earlier worked as the Senior Vice President of the Novartis Institute for Biomedical Research.
Robby E. Weimer IV, the CFO of Synthorx, was previously associated with The Geneva Finance LLC as a managing partner. He has other experiences in investment banking in JPMorgan Chase and Deutsche Bank.
Rachel H. Allen joined Synthorx as Senior Vice President and General Counsel in . She had earlier worked as Senior Vice President and General Counsel at MGI Pharma.
Jeffrey D. Stein is an Independent Director for Synthorx since . He currently serves as the CEO of Cidara Therapeutics and has experience in the biotech industry working for several notable pharmaceutical companies like Pfizer, Merck & Co., MedImmune, and others.
Jami Rubin is also an Independent Director, since She has earlier worked on Wall Street as a biotech analyst with investment banks like Goldman Sachs, Morgan Stanley and others.
Dirk Van Den Boom has been an Independent Director since . He served as the President and Chief Executive Officer of Molecular Stethoscope, Inc., and Vice President and General Manager of Applied Biosystems Division of Life Technologies Corporation.
|
